Raymond James Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $298
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $295 to $400
Alnylam Pharma (ALNY) Gets a Buy From Bernstein
Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $371
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $310
Alnylam Pharmaceuticals Is Maintained at Outperform by Bernstein
Alnylam Pharmaceuticals Analyst Ratings
Leerink Partners Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $304
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $296
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $296
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Announces Target Price $272
Scotiabank Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $384
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $275
No Data